The eponymous polio vaccine developed by Jonas Salk at the University of Pittsburgh is arguably misnamed. If the importance in its development of scientists besides Salk were to be fairly represented, it should have been called the Salk-Youngner vaccine. The key part played by virologist Julius Youngner was not, of course, so acknowledged. "Dr Salk really did go out of his way to put the other people that were involved in the background", explains Patricia Dowling, a virologist who was an associate professor in the same department as Youngner, and a colleague of long standing at Pittsburgh. "This hung very heavily around Juli's neck throughout his whole career. He really felt slighted", she adds. Youngner's role was well known within the scientific community, according to Saleem Khan, a Professor in the Department of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine. But he remained unknown to the public. Khan agrees that Salk's collaborators should have shared more of the credit. "But Salk was the leader, and he didn't allow it to happen."
Youngner studied microbiology at the University of Michigan, and stayed on as a faculty member until leaving in 1947 to join the National Cancer Institute (NCI) in Bethesda. It was 2 years later that he moved to the Virus Research Laboratory at the University of Pittsburgh and, Youngner's decision to make what was originally intended to be a temporary move from NCI to the University of Pittsburgh was motivated by his wish to culture viruses, an activity he was unable to pursue at NCI. At Pittsburgh, where Salk was already aiming to grow polio viruses, it was Youngner who cracked the problem. "He figured out a way to trypsinise the cells", says Khan. "He found a way to grow the polio virus in tissue culture using monkey kidney cells." The use of the enzyme trypsin to disaggregate tissue into its component cells was well established-but it was Youngner who introduced it into virology. In Dowling's view it was Youngner who "really made the vaccine", as she puts it. "Juli figured out how to grow the virus, how to inactivate it, and then he figured how to test the immune response to see if it worked."
If there is any marginally creditable explanation for Salk's behaviour, it perhaps lies in the view taken by The March of Dimes, the charitable body that raised money for polio research. "The man who ran it wanted to create a hero, to focus on one person in order to get more money", says Dowling. "He encouraged Jonas Salk to be a sort of superstar." But this wouldn't explain why, even years later, Salk was still happy to go on taking all the credit. That Salk behaved badly is now generally accepted, not least by his son Peter who has said how much he wishes his father had acknowledged his associates for their share in the work.
Much as Youngner resented his treatment, he did not allow it to interfere with the rest of his career. Among many other achievements he was the first to show that the production of interferon could be induced by organisms other than viruses. With a colleague, Samuel Salvin, he also identified what became known as type II or gamma interferon. And in the late 1990s he and Dowling used a live attenuated virus to develop what became a successful vaccine against equine influenza. "He was a person who actually liked doing science", says Khan. "He was still working with his hands well into his 70s. He didn't become someone who just wrote grant proposals and thought about ideas…Even after his retirement he worked in the lab." And Youngner was very self-effacing, according to Dowling. "I think he would have been more famous if he hadn't hidden from any kind of self-promotion." Unlike his old boss he was eager to give credit to colleagues. Youngner leaves a wife, Rina, and also a son, Stuart, and a daughter, Lisa, both from a previous marriage.
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